In molecular biology, a Morpholino is a kind of molecule used to modify gene expression. Morpholino oligonucleotides (oligos) are an antisense technology used to block access of other molecules to specific sequences within nucleic acid. Morpholinos block small (~25 base) regions of the base-pairing surfaces of ribonucleic acid (RNA). Morpholinos are sometimes referred to as PMO (phosphorodiamidate morpholino oligo). The word "morpholino" can occur in other chemical names, referring to chemicals containing a six-membered morpholine ring; this article discusses only the Morpholino antisense oligos.
Morpholinos are usually used as a research tool for reverse genetics by knocking down gene function. This is achieved by preventing cells from making a targeted protein or by modifying the splicing of pre-mRNA. Knocking down gene expression is a powerful method for learning about the function of a particular protein; similarly, causing a specific exon to be spliced out of a protein can help to determine the function of the protein moiety encoded by that exon. These molecules have been applied to studies in several model organisms, including mice, zebrafish and frogs.
Morpholinos are also in development as pharmaceutical therapeutics targeted against pathogenic organisms such as bacteria or viruses and for amelioration of genetic diseases. These synthetic oligos were conceived by James E. Summerton (Gene Tools, LLC) and developed in collaboration with Dwight D. Weller (AVI BioPharma Inc.).
Morpholinos are synthetic molecules which are the product of a redesign of natural nucleic acid structure. Usually 25 bases in length, they bind to complementary sequences of RNA by standard nucleic acid base-pairing. Structurally, the difference between Morpholinos and DNA is that while Morpholinos have standard nucleic acid bases, those bases are bound to morpholine rings instead of deoxyribose rings and linked through phosphorodiamidate groups instead of phosphates. This may be easiest to visualize by referring to the first figure and comparing the structures of the two strands depicted there, one of RNA and the other of a Morpholino. Replacement of anionic phosphates with the uncharged phosphorodiamidate groups eliminates ionization in the usual physiological pH range, so Morpholinos in organisms or cells are uncharged molecules. The entire backbone of a Morpholino is made from these modified subunits. Morpholinos are most commonly used as single-stranded oligos, though heteroduplexes of a Morpholino strand and a complementary DNA strand may be used in combination with cationic cytosolic delivery reagents.
Morpholinos do not degrade their target RNA molecules, unlike many antisense structural types (e.g. phosphorothioates, siRNA). Instead, Morpholinos act by "steric blocking", binding to a target sequence within an RNA and simply getting in the way of molecules which might otherwise interact with the RNA.
Morpholino oligos are often used to investigate the role of a specific mRNA transcript in an embryo. Developmental biologists inject Morpholino oligos into eggs or embryos of zebrafish, African clawed frog (Xenopus), chick, and sea urchin, producing morphant embryos. With appropriate cytosolic delivery systems, Morpholinos are effective in cell culture.
Morpholinos are being developed as pharmaceuticals under the name "NeuGenes" by AVI BioPharma Inc. They have been used in mammals ranging from mice to humans and some are currently being tested in clinical trials as anticancer therapies.
Normal gene expression in eukaryotes
In eukaryotic organisms, pre-mRNA is transcribed in the nucleus, introns are spliced out, then the mature mRNA is exported from the nucleus to the cytoplasm. The small subunit of the ribosome usually starts by binding to one end of the mRNA and is joined there by various other eukaryotic initiation factors, forming the initiation complex. The initiation complex scans along the mRNA strand until it reaches a start codon, and then the large subunit of the ribosome attaches to the small subunit and translation of a protein begins. This entire process is referred to as gene expression; it is the process by which the information in a gene, encoded as a sequence of bases in DNA, is converted into the structure of a protein. A Morpholino can modify splicing or block translation, depending on the Morpholino's base sequence.
Bound to the 5'-untranslated region of messenger RNA (mRNA), Morpholinos can interfere with progression of the ribosomal initiation complex from the 5' cap to the start codon. This prevents translation of the coding region of the targeted transcript (called "knocking down" gene expression). This is useful experimentally when an investigator wishes to know the function of a particular protein; Morpholinos provide a convenient means of knocking down expression of the protein and learning how that knockdown changes the cells or organism. Some Morpholinos knock down expression so effectively that, after degradation of preexisting proteins, the targeted proteins become undetectable by Western blot (e.g. figure 1 in:).
Modifying pre-mRNA splicing
Morpholinos can interfere with pre-mRNA processing steps either by preventing splice-directing small nuclear ribonucleoproteins (snRNP) complexes from binding to their targets at the borders of introns on a strand of pre-mRNA, or by blocking the nucleophilic adenine base and preventing it from forming the splice lariat structure, or by interfering with the binding of splice regulatory proteins such as splice silencers and splice enhancers.. Preventing the binding of snRNP U1 (at the donor site) or U2/U5 (at the polypyrimidine moiety and acceptor site) can cause modified splicing, commonly excluding exons from the mature mRNA. Targeting some splice targets results in intron inclusions, while activation of cryptic splice sites can lead to partial inclusions or exclusions. Targets of U11/U12 snRNPs can also be blocked. Splice modification can be conveniently assayed by reverse-transcriptase polymerase chain reaction (RT-PCR) and is seen as a band shift after gel electrophoresis of RT-PCR products.
Blocking other mRNA sites
Morpholinos have been used to block miRNA activity and maturation. They can block ribozyme activity. U2 and U12 snRNP functions have been inhibited by Morpholinos. Morpholinos targeted to "slippery" mRNA sequences within protein coding regions can induce translational frameshifts. Activities of Morpholinos against this variety of targets suggest that Morpholinos can be used as a general-purpose tool for blocking interactions of proteins or nucleic acids with mRNA.
Specificity, stability and non-antisense effects
Morpholinos have become a standard knockdown tool in animal embryonic systems, which have a broader range of gene expression than adult cells and can be strongly affected by an off-target interaction. Following initial injections into frog or fish embryos at the single-cell or few-cell stages, Morpholino effects can often be measured five days later, after most of the processes of organogenesis and differentiation are past, with observed phenotypes consistent with target-gene knockdown. Control oligos with irrelevant sequences usually produce no change in embryonic phenotype, evidence of the Morpholino oligo's sequence-specificity and lack of non-antisense effects.
mRNA rescue experiments can often restore the wild-type phenotype to the embryos and provide evidence for the specificity of a Morpholino. In an mRNA rescue, a Morpholino is co-injected with an mRNA that codes for the same protein that the Morphlino is targeted to knock down. However, the rescue mRNA has a modified 5'-UTR (untranslated region) so that the rescue mRNA contains no target for the Morpholino but the rescue mRNA's coding region encodes the protein of interest. Translation of the rescue mRNA replaces production of the protein which was knocked down by the Morpholino. Since the rescue mRNA would not affect phenotypic changes due to modulation of off-target gene expression by the Morpholino, this return to wild-type phenotype is further evidence of Morpholino specificity.
Because of their completely unnatural backbones, Morpholinos are not recognized by cellular proteins. Nucleases do not degrade Morpholinos, nor are they degraded in serum or in cells . Morpholinos do not activate toll-like receptors and so they do not activate innate immune responses such as interferon induction or the NF-κB mediated inflammation response. Morpholinos are not known to modify methylation of DNA.
A cause for concern in the use of Morpholinos is the potential for "off target" effects. Up to 18% of Morpholinos appear to have non-target related phenotypes including cell death in the central nervous system and somite tissues of zebrafish embryos. Most of these effects have been shown to be due to activation of p53-mediated apoptosis, and can be suppressed by co-injection of an anti-p53 Morpholino along with the experimental Morpholino. It appears that these effects are sequence specific, as in most cases if a Morpholino is associated with non-target effects, the 4-base mismatch Morpholino will not trigger these effects. The question of whether an observed morphant phenotype is due to the intended knockdown or an off-target interaction can often be addressed by running another experiment to confirm that the observed morphant phenotype results from the knockdown of the expected target. This can be done by recapitulating the morphant phenotype with a second, non-overlapping Morpholino targeting the same mRNA or by confirmation of the observed phenotypes by use of a mutant strain or dominant negative methods. As mentioned above, rescue of observed phenotypes by coinjecting a rescue mRNA is, when feasible, a reliable test of specificity of a Morpholino.
For a Morpholino to be effective, it must be delivered past the cell membrane into the cytosol of a cell. Once in the cytosol, Morpholinos freely diffuse between the cytosol and nucleus, as demonstrated by the nuclear splice-modifying activity of Morpholinos observed after microinjection into the cytosol of cells. Different methods are used for delivery into embryos, into cultured cells or into adult animals. A microinjection apparatus is usually used for delivery into an embryo, with injections most commonly performed at the single-cell or few-cell stage; an alternative method for embryonic delivery is electroporation, which can deliver oligos into tissues of later embryonic stages. Common techniques for delivery into cultured cells include the Endo-Porter peptide (which causes the Morpholino to be released from endosomes), the Special Delivery system (using a Morpholino-DNA heteroduplex and an ethoxylated polyethylenimine delivery reagent), electroporation or scrape loading. Delivery into adult tissues is usually difficult, though there are a few systems allowing useful uptake of unmodified Morpholino oligos (including the inherently leaky muscle cells caused by Duchenne muscular dystrophy or the vascular endothelial cells stressed during balloon angioplasty). Systemic delivery into many cells in adult organisms can be accomplished by using covalent conjugates of Morpholino oligos with cell penetrating peptides, and while some toxicity has been associated with the peptides they have been used in vivo for effective oligo delivery at doses below those causing observed toxicity.
- Summerton, J (1999). "Morpholino Antisense Oligomers: The Case for an RNase-H Independent Structural Type" (Pubmed). Biochimica et Biophysica Acta. 1489: 141–58.
- Draper, BW (2001). "Inhibition of zebrafish fgf8 pre-mRNA splicing with morpholino oligos: A quantifiable method for gene knockdown" (Pubmed). Genesis. 30 (3): 154–6. Unknown parameter
- Heasman J (2002). "Morpholino oligos: making sense of antisense?". Dev. Biol. 243 (2): 209–14. PMID 11884031.
- Geller BL (2005). "Antibacterial antisense". Curr. Opin. Mol. Ther. 7 (2): 109–13. PMID 15844617.
- Deas, TS (2007). "In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus" (Pubmed). Antimicrob Agents Chemother.: Epub ahead of print. Unknown parameter
- McClorey, G (2006). "Induced dystrophin exon skipping in human muscle explants" (Pubmed). Neuromuscul Disord. 16 (9–10): 583–90. Unknown parameter
- Summerton, J (1997). "Morpholino Antisense Oligomers: Design, Preparation and Properties" (Pubmed). Antisense & Nucleic Acid Drug Development. 7*: 187–95. Unknown parameter
- Morcos, PA (2001). "Achieving efficient delivery of morpholino oligos in cultured cells" (Pubmed). Genesis. 30 (3): 94–102.
- Nasevicius, A (2000). "Effective targeted gene 'knockdown' in zebrafish" (Pubmed). Nature Genetics. 26 (2): 216–20. Unknown parameter
- Heasman, J (2000). "Beta-catenin signaling activity dissected in the early Xenopus embryo: a novel antisense approach" (Pubmed). Developmental Biology. 222: 124–34. Unknown parameter
- Kos, R (2001). "The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos" (Pubmed). Development. 128 (8): 1467–79. Unknown parameter
- Howard, EW (2001). "SpKrl: a direct target of (beta)-catenin regulation required for endoderm differentiation in sea urchin embryos" (Pubmed). Development. 128 (3): 365–75. Unknown parameter
- Coonrod, SA (2001). "A morpholino phenocopy of the mouse MOS mutation" (Pubmed). Genesis. 30 (3): 198–200. Unknown parameter
- Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL (2005). "In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors". Clin. Cancer Res. 11 (10): 3930–8. PMID 15897595.
- Stancheva, I (2003). "A mutant form of MeCP2 protein associated with human Rett syndrome cannot be displaced from methylated DNA by notch in Xenopus embryos" (Pubmed). Mol Cell. 12 (2): 425–35. Unknown parameter
- Bruno, IG (2004). "Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements" (Pubmed). Hum Mol Genet. 3 (20): 2409–20. Unknown parameter
- Vetrini, F (2006). "Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides" (Pubmed). Hum Mutat. 27 (5): 420–6. Unknown parameter
- Morcos, PA (2007). "Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos" (Pubmed). Biochem Biophys Res Commun.
- Kloosterman, WP (2004). "Substrate requirements for let-7 function in the developing zebrafish embryo" (Pubmed). Nucleic Acids Res. 32 (21): 6284–91. Unknown parameter
- Flynt, AS (2007). "Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate". Nature Genetics (Pubmed)
|url=(help). 39: 259–263. Unknown parameter
- Kloosterman, WP (2007). "Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development" (Pubmed). PLoS Biol. 5 (8): e203. Unknown parameter
- Yen, L (2004). "Exogenous control of mammalian gene expression through modulation of RNA self-cleavage" (Pubmed). Nature. 431 (7007): 471–6. Unknown parameter
- Matter, N (2005). "Targeted 'knockdown' of spliceosome function in mammalian cells" (Pubmed). Nucleic Acids Res. 33 (4): e41. Unknown parameter
- Howard, MT (2004). "Efficient stimulation of site-specific ribosome frameshifting by antisense oligonucleotides" (Pubmed). RNA. 10 (10): 1653–61. Unknown parameter
- Hudziak, RM (1996). "Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation" (Pubmed). Antisense Nucleic Acid Drug Dev. 6 (4): 267–72. Unknown parameter
- Youngblood, DS (2007). "Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells" (Pubmed). Bioconjug Chem. 18 (1): 50–60. Unknown parameter
- Ekker, SC (2001). "Morphant Technology in Model Developmental Systems" (Pubmed). Genesis. 30 (3): 89–93. Unknown parameter
- Robu, ME (2007). "p53 activation by knockdown technologies" (Pubmed). PLoS Genetics. 3 (5): e78. Unknown parameter
- Cerda, GA (2006). "Electroporation of DNA, RNA, and morpholinos into zebrafish embryos" (Pubmed). Methods. 39 (3): 207–11. Unknown parameter
- Summerton, JE (2005). "Endo-porter: a novel reagent for safe, effective delivery of substances into cells" (Pubmed). Ann N Y Acad Sci. 1058: 62–75.
- Jubin, R (2004). "Optimizing electroporation conditions for intracellular delivery of morpholino antisense oligonucleotides directed against the hepatitis C virus internal ribosome entry site" (Pubmed). Methods Mol Med. 106: 309–22.
- Partridge, M (1996). "A simple method for delivering morpholino antisense oligos into the cytoplasm of cells" (Pubmed). Antisense Nucleic Acid Drug Dev. 6 (3): 169–75. Unknown parameter
- Fletcher, S (2006). "Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide" (Pubmed). J Gene Med. 8 (2): 207–16. Unknown parameter
- Kipshidze, NN (2002). "Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model" (Pubmed). J Am Coll Cardiol. 39 (10): 1686–91. Unknown parameter
- Abes, S (2006). "Vectorization of morpholino oligomers by the (R-Ahx-R)(4) peptide allows efficient splicing correction in the absence of endosomolytic agents" (Pubmed). J Control Release. 116 (3): 304–13. Unknown parameter
- Burrer, R (2007). "Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models" (Pubmed). J. Virol. 81 (11): 5637–48. Unknown parameter
- Amantana, A (2007). "Pharmacokinetics, Biodistribution, Stability and Toxicity of a Cell-Penetrating Peptide-Morpholino Oligomer Conjugate" (Pubmed). Bioconjug Chem. [Epub ahead of print]. Unknown parameter
- Gene Tools, LLC 
- Wiley-Liss, Inc. Special Issue: Morpholino Gene Knockdowns of genesis Volume 30, Issue 3 Pages 89-200 (July 2001). A special issue of Genesis, comprised of a series of peer-reviewed short papers utilizing morpholino knock downs of gene function in various animal and tissue culture systems.
- Moulton, Jon (2007), "Using Morpholinos to Control Gene Expression (Unit 4.30)", in Beaucage, Serge, Current Protocols in Nucleic Acid Chemistry, New Jersey: John Wiley & Sons, Inc., ISBN 978-0-471-24662-6